A Chinese research team attached to the military started 2nd clinical trial for coronavirus vaccine 中国军事科学院研究团队研发的新冠病毒疫苗进入II期人体临床试验阶段

2020-04-15 08:40:35 source: Economic Daily


1.jpeg


On April 12, the recombinant COVID-19 vaccine (adenoviral vector) developed by a research team led by Academician Chen Wei of the academy of Military Medical Sciences have entered clinical trials officially in Wuhan. It is the first vaccine for coronavirus that has entered the II phases clinical trial in the world. On the morning of April.13, in Wuhan, accompanied by his daughter Xiong Ying, an 84-year old elderly Xiong Zhengxing completed the inoculation of recombinant COVID-19 vaccine and he is the oldest among this II phases clinical trial in the world so far. 

 

The II phases clinical trial of recombinant COVID-19 vaccine (adenoviral vector) is led by the CDC of Jiangsu Province and undertook jointly by the CDC of Hubei Province and Zhongnan Hospital of Wuhan University. It is a genetically engineered vaccine candidate with the replication-defective adenovirus type 5 as the vector to express SARS-CoV-2 spike protein. The vaccine candidate is intended to be used to prevent the disease caused by the novel coronavirus infection.

 

In the I phase of the clinical trial of this vaccine, the researchers focused on its safety while the focus of the second phase will be on its efficacy.


Different from the I phases, the II phases clinical trial has more volunteers with 500 volunteers and it also includes a placebo control group.

 

The current global anti-epidemic situation is extremely grim. As an effective product for people’s health, vaccines are very essential for epidemic prevention and control. Therefore, the II phases clinical trial of COVID-19 will affect the future of the anti-pandemic globally.


4月12日,由军事科学院军事医学研究所生物工程研究所陈薇院士团队牵头研发的重组新冠病毒(腺病毒载体)疫苗正式在武汉开始受试者接种试验。这是全球首款进入II期人体临床试验的新冠病毒疫苗。4月13日上午,84岁高龄的武汉老人熊正兴在女儿熊英的陪同下完成了重组新冠病毒疫苗的接种,成为目前全球首个新冠病毒疫苗II期临床试验中的年龄最高的志愿者。

 

此次重组新冠病毒(腺病毒载体)疫苗II期临床试验由江苏省疾控中心牵头,湖北省疾控中心与武汉大学中南医院共同承担完成。重组新冠病毒(腺病毒载体)疫苗采用基因工程方法构建,以复制缺陷型人5型腺病毒为载体,可表达新型冠状病毒S抗原,用于预防新型冠状病毒感染引起的疾病。

 

疫苗的I期人体临床试验注重安全性,而II期人体临床试验则注重有效性。与I期试验不同,II期临床试验规模更大,多达500人,且引入了安慰剂对照组。


当前全球抗疫形势极其严峻,疫苗作为用于健康人的特殊产品,对疫情防控至关重要。随着陈薇院士团队的重组新冠病毒疫苗进入II期人体临床试验,这也意味着疫苗II期人体临床试验情况将影响全球抗疫的未来形势。


 

 

 (Executive Editor: Ye Ke)

read more

11881292 A Chinese research team attached to the military started 2nd clinical trial for coronavirus vaccine 中国军事科学院研究团队研发的新冠病毒疫苗进入II期人体临床试验阶段 public html

1.jpeg


On April 12, the recombinant COVID-19 vaccine (adenoviral vector) developed by a research team led by Academician Chen Wei of the academy of Military Medical Sciences have entered clinical trials officially in Wuhan. It is the first vaccine for coronavirus that has entered the II phases clinical trial in the world. On the morning of April.13, in Wuhan, accompanied by his daughter Xiong Ying, an 84-year old elderly Xiong Zhengxing completed the inoculation of recombinant COVID-19 vaccine and he is the oldest among this II phases clinical trial in the world so far. 

 

The II phases clinical trial of recombinant COVID-19 vaccine (adenoviral vector) is led by the CDC of Jiangsu Province and undertook jointly by the CDC of Hubei Province and Zhongnan Hospital of Wuhan University. It is a genetically engineered vaccine candidate with the replication-defective adenovirus type 5 as the vector to express SARS-CoV-2 spike protein. The vaccine candidate is intended to be used to prevent the disease caused by the novel coronavirus infection.

 

In the I phase of the clinical trial of this vaccine, the researchers focused on its safety while the focus of the second phase will be on its efficacy.


Different from the I phases, the II phases clinical trial has more volunteers with 500 volunteers and it also includes a placebo control group.

 

The current global anti-epidemic situation is extremely grim. As an effective product for people’s health, vaccines are very essential for epidemic prevention and control. Therefore, the II phases clinical trial of COVID-19 will affect the future of the anti-pandemic globally.


4月12日,由军事科学院军事医学研究所生物工程研究所陈薇院士团队牵头研发的重组新冠病毒(腺病毒载体)疫苗正式在武汉开始受试者接种试验。这是全球首款进入II期人体临床试验的新冠病毒疫苗。4月13日上午,84岁高龄的武汉老人熊正兴在女儿熊英的陪同下完成了重组新冠病毒疫苗的接种,成为目前全球首个新冠病毒疫苗II期临床试验中的年龄最高的志愿者。

 

此次重组新冠病毒(腺病毒载体)疫苗II期临床试验由江苏省疾控中心牵头,湖北省疾控中心与武汉大学中南医院共同承担完成。重组新冠病毒(腺病毒载体)疫苗采用基因工程方法构建,以复制缺陷型人5型腺病毒为载体,可表达新型冠状病毒S抗原,用于预防新型冠状病毒感染引起的疾病。

 

疫苗的I期人体临床试验注重安全性,而II期人体临床试验则注重有效性。与I期试验不同,II期临床试验规模更大,多达500人,且引入了安慰剂对照组。


当前全球抗疫形势极其严峻,疫苗作为用于健康人的特殊产品,对疫情防控至关重要。随着陈薇院士团队的重组新冠病毒疫苗进入II期人体临床试验,这也意味着疫苗II期人体临床试验情况将影响全球抗疫的未来形势。


 

 

 (Executive Editor: Ye Ke)

]]>
vaccine;phases;clinical;trials;临床试验;Wuhan;April;Xiong;world;疫苗